直播预告:共画罕见病很大同心圆:国际罕见病日

2022-02-28 网络 网络

国家首批罕见病目录影响力评估报告发布会暨2022全国罕见病诊疗与保障研讨会将于02月28日13:30-18:00召开。

国家首批罕见病目录影响力评估报告发布会暨2022全国罕见病诊疗与保障研讨会将于02月28日13:30-18:00召开。本次会议由蔻德罕见病中心与健识局共同主办,梅斯医学将受邀共同参与本次会议。

同日,蔻德罕见病中心创始人黄如方先生将联合12位科学家和企业家将共同发起浙江瑞鸥公益基金会。

梅斯医学董事长张发宝博士作为受邀嘉宾,将与行业各界大佬一起进行圆桌讨论,探讨加速中国在全球罕见病科研与转化医学上的推动。

届时,您可以扫码进入直播间,观看会议

图片

 

长按识别二维码观看直播

(会议时间:2月28日13:30-18:00)

会议抢先看

Part1国家首批罕见病目录影响力评估报告发布会&研讨会

会议将由主办方对本次调研报告做发言致辞,并邀请相关嘉宾发表主体报告演讲,最后还讲开展圆桌会议《2022全国罕见病诊疗与保障研讨》,与行业各界人士共同探讨罕见病诊疗相关话题,积极推动中国罕见病基础科研和转化医学事业发展。愿罕见病患者早日得到有效治疗,并早日康复。

Part2首届“蜗牛快跑”罕见病公益跑项目启动

图片

蜗牛,它背着重重的壳,爬行速度很慢,但却一直向前。罕见病患者和家人就像蜗牛一样,扛着沉重的精神和经济压力,在大家看不到的黑暗中,负重前行。本次会议主办方通过趣味跑和负重跑两种形式让更多人去感受罕见病群体的感受,并正式启动首届“蜗牛快跑”罕见病公益跑项目。

Part3聚焦罕见病科研推动,成立:浙江瑞鸥公益基金会

“下一个十年,我们会聚集一批有情怀的企业家和科学家,真正地去推动中国罕见病基础科研和转化医学事业。”在2021年第十届中国罕见病高峰论坛上,蔻德罕见病中心创始人黄如方先生如是说。而想要实现这个大大的梦想,他已经为此谋划了三年,拜访过几十位行业大咖,游说他们和他一起来推动中国罕见病科研发展。

本届会上,黄如方将联合12位科学家和企业家将共同发起浙江瑞鸥公益基金会,梅斯医学创始人张发宝博士将受邀参与基金会成立仪式,并同行业众多大佬一起探讨,加速中国在全球罕见病科研与转化医学上的推动。期待更多行业同仁能共同见证这一时刻。

 

图片

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1952483, encodeId=c452195248366, content=<a href='/topic/show?id=54b34114ec7' target=_blank style='color:#2F92EE;'>#国际罕见病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41147, encryptionId=54b34114ec7, topicName=国际罕见病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4a4d285, createdName=日月, createdTime=Thu Oct 27 03:25:50 CST 2022, time=2022-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1467646, encodeId=23bf146e64620, content=<a href='/topic/show?id=ef32e9539e8' target=_blank style='color:#2F92EE;'>#罕见#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79539, encryptionId=ef32e9539e8, topicName=罕见)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29f36868190, createdName=syscxl, createdTime=Wed Mar 02 01:25:50 CST 2022, time=2022-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1198369, encodeId=fe9d11983693e, content=具体表现较好, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6e6b1427673, createdName=matthaus10zsd, createdTime=Tue Mar 01 14:47:50 CST 2022, time=2022-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1198368, encodeId=d9e0119836809, content=👌!, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6e6b1427673, createdName=matthaus10zsd, createdTime=Tue Mar 01 14:47:29 CST 2022, time=2022-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1198196, encodeId=f4411198196c8, content=如何回看?, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=94186528697, createdName=ms2000000767990719, createdTime=Mon Feb 28 23:03:25 CST 2022, time=2022-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1197997, encodeId=4f3e119e997c5, content=关注罕见病!, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210426/763e7ce2dab140888e41ebc5fca8c4b7/61843205f4d644369d57d751f29054a3.jpg, createdBy=8ba35478954, createdName=ms9000000883963153, createdTime=Mon Feb 28 13:12:36 CST 2022, time=2022-02-28, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1952483, encodeId=c452195248366, content=<a href='/topic/show?id=54b34114ec7' target=_blank style='color:#2F92EE;'>#国际罕见病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41147, encryptionId=54b34114ec7, topicName=国际罕见病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4a4d285, createdName=日月, createdTime=Thu Oct 27 03:25:50 CST 2022, time=2022-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1467646, encodeId=23bf146e64620, content=<a href='/topic/show?id=ef32e9539e8' target=_blank style='color:#2F92EE;'>#罕见#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79539, encryptionId=ef32e9539e8, topicName=罕见)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29f36868190, createdName=syscxl, createdTime=Wed Mar 02 01:25:50 CST 2022, time=2022-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1198369, encodeId=fe9d11983693e, content=具体表现较好, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6e6b1427673, createdName=matthaus10zsd, createdTime=Tue Mar 01 14:47:50 CST 2022, time=2022-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1198368, encodeId=d9e0119836809, content=👌!, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6e6b1427673, createdName=matthaus10zsd, createdTime=Tue Mar 01 14:47:29 CST 2022, time=2022-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1198196, encodeId=f4411198196c8, content=如何回看?, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=94186528697, createdName=ms2000000767990719, createdTime=Mon Feb 28 23:03:25 CST 2022, time=2022-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1197997, encodeId=4f3e119e997c5, content=关注罕见病!, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210426/763e7ce2dab140888e41ebc5fca8c4b7/61843205f4d644369d57d751f29054a3.jpg, createdBy=8ba35478954, createdName=ms9000000883963153, createdTime=Mon Feb 28 13:12:36 CST 2022, time=2022-02-28, status=1, ipAttribution=)]
    2022-03-02 syscxl
  3. [GetPortalCommentsPageByObjectIdResponse(id=1952483, encodeId=c452195248366, content=<a href='/topic/show?id=54b34114ec7' target=_blank style='color:#2F92EE;'>#国际罕见病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41147, encryptionId=54b34114ec7, topicName=国际罕见病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4a4d285, createdName=日月, createdTime=Thu Oct 27 03:25:50 CST 2022, time=2022-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1467646, encodeId=23bf146e64620, content=<a href='/topic/show?id=ef32e9539e8' target=_blank style='color:#2F92EE;'>#罕见#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79539, encryptionId=ef32e9539e8, topicName=罕见)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29f36868190, createdName=syscxl, createdTime=Wed Mar 02 01:25:50 CST 2022, time=2022-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1198369, encodeId=fe9d11983693e, content=具体表现较好, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6e6b1427673, createdName=matthaus10zsd, createdTime=Tue Mar 01 14:47:50 CST 2022, time=2022-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1198368, encodeId=d9e0119836809, content=👌!, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6e6b1427673, createdName=matthaus10zsd, createdTime=Tue Mar 01 14:47:29 CST 2022, time=2022-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1198196, encodeId=f4411198196c8, content=如何回看?, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=94186528697, createdName=ms2000000767990719, createdTime=Mon Feb 28 23:03:25 CST 2022, time=2022-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1197997, encodeId=4f3e119e997c5, content=关注罕见病!, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210426/763e7ce2dab140888e41ebc5fca8c4b7/61843205f4d644369d57d751f29054a3.jpg, createdBy=8ba35478954, createdName=ms9000000883963153, createdTime=Mon Feb 28 13:12:36 CST 2022, time=2022-02-28, status=1, ipAttribution=)]
    2022-03-01 matthaus10zsd

    具体表现较好

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1952483, encodeId=c452195248366, content=<a href='/topic/show?id=54b34114ec7' target=_blank style='color:#2F92EE;'>#国际罕见病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41147, encryptionId=54b34114ec7, topicName=国际罕见病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4a4d285, createdName=日月, createdTime=Thu Oct 27 03:25:50 CST 2022, time=2022-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1467646, encodeId=23bf146e64620, content=<a href='/topic/show?id=ef32e9539e8' target=_blank style='color:#2F92EE;'>#罕见#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79539, encryptionId=ef32e9539e8, topicName=罕见)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29f36868190, createdName=syscxl, createdTime=Wed Mar 02 01:25:50 CST 2022, time=2022-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1198369, encodeId=fe9d11983693e, content=具体表现较好, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6e6b1427673, createdName=matthaus10zsd, createdTime=Tue Mar 01 14:47:50 CST 2022, time=2022-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1198368, encodeId=d9e0119836809, content=👌!, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6e6b1427673, createdName=matthaus10zsd, createdTime=Tue Mar 01 14:47:29 CST 2022, time=2022-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1198196, encodeId=f4411198196c8, content=如何回看?, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=94186528697, createdName=ms2000000767990719, createdTime=Mon Feb 28 23:03:25 CST 2022, time=2022-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1197997, encodeId=4f3e119e997c5, content=关注罕见病!, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210426/763e7ce2dab140888e41ebc5fca8c4b7/61843205f4d644369d57d751f29054a3.jpg, createdBy=8ba35478954, createdName=ms9000000883963153, createdTime=Mon Feb 28 13:12:36 CST 2022, time=2022-02-28, status=1, ipAttribution=)]
    2022-03-01 matthaus10zsd

    👌!

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1952483, encodeId=c452195248366, content=<a href='/topic/show?id=54b34114ec7' target=_blank style='color:#2F92EE;'>#国际罕见病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41147, encryptionId=54b34114ec7, topicName=国际罕见病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4a4d285, createdName=日月, createdTime=Thu Oct 27 03:25:50 CST 2022, time=2022-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1467646, encodeId=23bf146e64620, content=<a href='/topic/show?id=ef32e9539e8' target=_blank style='color:#2F92EE;'>#罕见#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79539, encryptionId=ef32e9539e8, topicName=罕见)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29f36868190, createdName=syscxl, createdTime=Wed Mar 02 01:25:50 CST 2022, time=2022-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1198369, encodeId=fe9d11983693e, content=具体表现较好, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6e6b1427673, createdName=matthaus10zsd, createdTime=Tue Mar 01 14:47:50 CST 2022, time=2022-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1198368, encodeId=d9e0119836809, content=👌!, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6e6b1427673, createdName=matthaus10zsd, createdTime=Tue Mar 01 14:47:29 CST 2022, time=2022-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1198196, encodeId=f4411198196c8, content=如何回看?, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=94186528697, createdName=ms2000000767990719, createdTime=Mon Feb 28 23:03:25 CST 2022, time=2022-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1197997, encodeId=4f3e119e997c5, content=关注罕见病!, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210426/763e7ce2dab140888e41ebc5fca8c4b7/61843205f4d644369d57d751f29054a3.jpg, createdBy=8ba35478954, createdName=ms9000000883963153, createdTime=Mon Feb 28 13:12:36 CST 2022, time=2022-02-28, status=1, ipAttribution=)]
    2022-02-28 ms2000000767990719

    如何回看?

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1952483, encodeId=c452195248366, content=<a href='/topic/show?id=54b34114ec7' target=_blank style='color:#2F92EE;'>#国际罕见病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41147, encryptionId=54b34114ec7, topicName=国际罕见病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4a4d285, createdName=日月, createdTime=Thu Oct 27 03:25:50 CST 2022, time=2022-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1467646, encodeId=23bf146e64620, content=<a href='/topic/show?id=ef32e9539e8' target=_blank style='color:#2F92EE;'>#罕见#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79539, encryptionId=ef32e9539e8, topicName=罕见)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29f36868190, createdName=syscxl, createdTime=Wed Mar 02 01:25:50 CST 2022, time=2022-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1198369, encodeId=fe9d11983693e, content=具体表现较好, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6e6b1427673, createdName=matthaus10zsd, createdTime=Tue Mar 01 14:47:50 CST 2022, time=2022-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1198368, encodeId=d9e0119836809, content=👌!, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6e6b1427673, createdName=matthaus10zsd, createdTime=Tue Mar 01 14:47:29 CST 2022, time=2022-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1198196, encodeId=f4411198196c8, content=如何回看?, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=94186528697, createdName=ms2000000767990719, createdTime=Mon Feb 28 23:03:25 CST 2022, time=2022-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1197997, encodeId=4f3e119e997c5, content=关注罕见病!, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210426/763e7ce2dab140888e41ebc5fca8c4b7/61843205f4d644369d57d751f29054a3.jpg, createdBy=8ba35478954, createdName=ms9000000883963153, createdTime=Mon Feb 28 13:12:36 CST 2022, time=2022-02-28, status=1, ipAttribution=)]
    2022-02-28 ms9000000883963153

    关注罕见病!

    0

相关资讯

IQVIA艾昆纬和百度健康在罕见病领域达成战略合作 构建以患者为中心的数字化解决方案--正本清源 缩短患者旅程

IQVIA艾昆纬(下简称“IQVIA”)和百度健康正式达成战略合作,基于罕见病患者全就诊旅程的痛点,以价值医疗为导向,为患者提供一站式的数字化解决方案。

从常规血气到代谢再到基因检测,罕见病例快速、精准检验全过程

临床上常规生化等检测难以对MCD确诊,常需要检测氨基酸和酰基肉碱谱联合尿液有机酸谱对MCD进行筛查诊断。

罕见病临床试验挑战与研究设计方法(梅斯医学)

目前有7000-8000种已知的罕见疾病,尽管在过去20年中与罕见病相关的研究已经有了很大的进展,但绝大多数罕见病还未获得批准治疗方法。研究人员研发罕见病治疗药物面临包括临床试验设计和临床试验有效开展

NEJM:这种10岁前就会死亡的罕见病,被慢病毒基因疗法修复了

Hurler综合征,也叫粘多糖病I-H型,是一种罕见的常染色体隐性遗传病。由于基因突变导致α-L-艾杜糖醛酸苷酶(IDUA)缺乏,进而导致粘多糖分解受阻,在体内堆积。是粘多糖病中最常见和最严重的类型。

“脊髓性肌萎缩症康复管理”专家第二次研讨会于线上顺利举办

脊髓性肌萎缩症(SMA)是由于运动神经元存活基因1(SMN1)缺失或突变导致功能性SMN蛋白不足而引起的一种常染色体隐性遗传性疾病,主要临床特征为肌无力和肌萎缩。